Polyclonal Antibody to Thrombin Activatable Fibrinolysis Inhibitor (TAFI)
| Code | Size | Price |
|---|
| PAA615Ra01-20ul | 20ul | £86.00 |
Quantity:
| PAA615Ra01-100ul | 100ul | £158.00 |
Quantity:
| PAA615Ra01-200ul | 200ul | £214.00 |
Quantity:
| PAA615Ra01-1ml | 1ml | £488.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
TAFI; CPU; PCPB; Thrombin Activatable Fibrinolysis Inhibitor; Plasma Carboxypeptidase B; Carboxypeptidase U
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Carboxypeptidase B2
Reactivity:
Hu;Mu;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:210-800
Immunohistochemistry: 5-20ug/mL;1:21-80
Immunocytochemistry: 5-20ug/mL;1:21-80
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:21-80
Immunocytochemistry: 5-20ug/mL;1:21-80
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Thrombin Activatable Fibrinolysis Inhibitor (TAFI) | RPA615Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||